Brief: Anebulo Pharmaceuticals Announces Completion Of Dosing, Preliminary Data From Part B Of Its Phase 2 Study Of ANEB-001

Anebulo Pharmaceuticals

09/01/2023 13:10

Jan 9 (Reuters) - Anebulo Pharmaceuticals Inc  ANEB.O :
    * ANEBULO PHARMACEUTICALS ANNOUNCES COMPLETION OF DOSING AND
PRELIMINARY DATA FROM PART B OF ITS PHASE 2 STUDY OF ANEB-001
FOR ACUTE CANNABINOID INTOXICATION
    * ANEBULO PHARMACEUTICALS INC - COMPANY TARGETING AN END OF
PHASE
2A MEETING WITH FDA IN FIRST HALF OF 2023
    * ANEBULO PHARMACEUTICALS INC - FULL PK, PD, AND SAFETY DATA
EXPECTED BY END OF 1Q2023
    * ANEBULO PHARMACEUTICALS INC - DELAYED DOSING OF ANEB-001
RAPIDLY
REVERSED PRE-EXISTING THC EFFECTS
    * ANEBULO PHARMACEUTICALS INC - PRELIMINARY DATA SHOWED
ANEB-001
REDUCED EFFECTS OF A 30 MG DOSE OF THC

Source text for Eikon:  ID:nBw6zLBN7a 
Further company coverage:  ANEB.O 
 ((Reuters.Briefs@thomsonreuters.com;))